1 / 29

TUMORS OF THE SALIVARY GLANDS

TUMORS OF THE SALIVARY GLANDS. TUMORS OF THE SALIVARY GLANDS MASSES. DIFFERENTIAL DIAGNOSIS OF A SALIVARY GLAND MASS: INFLAMMATION (PAROTIDITIS) MUMPS CALCULI NEOPLASM. TUMORS OF THE SALIVARY GLANDS. INCIDENCE: 3/100,000 3%ALL BODY TUMORS

willa
Download Presentation

TUMORS OF THE SALIVARY GLANDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TUMORS OF THE SALIVARY GLANDS

  2. TUMORS OF THE SALIVARY GLANDS MASSES • DIFFERENTIAL DIAGNOSIS OF A SALIVARY GLAND MASS: • INFLAMMATION (PAROTIDITIS) • MUMPS • CALCULI • NEOPLASM

  3. TUMORS OF THE SALIVARY GLANDS • INCIDENCE: 3/100,000 • 3%ALL BODY TUMORS • LOCATION OF SALIVARY GLAND TUMORS: 85% PAROTID, 10% SUBMANDIBULAR, 1% SUBLINGUAL, 4-5% MINOR SALIVARY GLANDS

  4. TUMORS OF THE SALIVARY GLANDS BENIGN MASSES • 80%OF ALL BENIGN LESIONS ARISE IN THE LATERAL (TAIL) OF THE PAROTID GLAND. • SUPERFICIAL PAROTIDECTOMY WITH PRESERVATION OF THE FACIAL NERVE • TOTAL SUBMANDIBULAR AND SUBLINGUAL GLAND RESECTION

  5. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESPLEOMORPHIC ADENOMA • BENIGN MIXED TUMOR • MYOEPITHELIAL AND EPIDERMOID CELL ORIGIN • MOST COMMON NEOPLASM IN THE PAROTID GLAND ACCOUNTS FOR 65% OF ALL OF THE PAROTID TUMORS.

  6. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESPLEOMORPHIC ADENOMA • TREATMENT: WIDE RESECTION OF THE TUMOR • AVOID SHELLING OUT THE LESION • RECURRENCE: PRIMARY DUE TO INADEQUATE RESECTION • LESIONS ARE MORE AGGRESSIVE WHEN THEY RECUR.

  7. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESWARTHIN’S TUMOR (ADENOLYMPHOMA) • SECOND MOST COMMON PAROTID TUMOR • MALE : FEMALE 5 : 1 • BILATERAL 10% • PRIMARILY LOCATED IN THE LATERAL GLAND HOWEVER MULTICENTRICITY IS DESCRIBED. • PEA SOUP BROWN MUCOID MATERIAL ON SECTIONING • TREATMENT: LATERAL OR TOTAL GLANDULAR RESECTION

  8. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESWARTHIN’S TUMOR (ADENOLYMPHOMA) • 90%CURED WITH RESECTION • 10%RECUR DUE TO MULTICENTRICITY OR INADEQUATE RESECTION.

  9. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESONCOCYTOMA • PRINCIPALLY A PAROTID GLAND TUMOR • 5TH DECADE • PROBABLY DUE TO HYPERPLASIA FROM AGING • >1%SALIVARY GLAND TUMORS • CYSTIC COMPONENT HAS BEEN IDENTIFIED.

  10. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESBASAL CELL ADENOMA • COMMON IN THE LATERAL PAROTID AND THE SUBMUCOSAL GLANDS IN THE UPPER LIP. • TREATMENT: LATERAL OR TOTAL GLANDULAR RESECTION.

  11. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESHEMANGIOMA • 50%OF ALL PAROTID TUMORS IN CHILDREN • TREATMENT: ENVOLUTION BY THE AGE OF 5 IS COMMON • CN VII: SUPERFICIAL LOCATION IN CHILDREN THUS OPERATIVE INTERVENTION SHOULD BE AVOIDED AND LET ENVOLUTION PROCEED UNLESS THERE IS UNCONTROLLED BLEEDING. • STEROID THERAPY

  12. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESLIPOMA • 4%OF ALL PAROTID TUMORS • MALE PREDOMINANCE • 4-5%TH DECADE • TREATMENT: LATERAL OR TOTAL GLANDULAR RESECTION

  13. TUMORS OF THE SALIVARY GLANDS BENIGN MASSESMYXOMA • SLOW GROWING • INFILTRATIVE • TREATMENT: WIDE RESECTION OR TOTAL GLANDULAR REMOVAL

  14. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSES • PROGNOSIS: PALATE > PAROTID > SUBMANDIBULAR / SUBLINGUAL GLAND • 5TH-6TH DECADE • RATE OF GROWTH DOES NOT CORRELATE WITH THE DEGREE OF MALIGNANCY • LUNG/BONE: PRIMARY METASTATIC SITES • PRIOR RADIOTHERAPY INCREASES THE RISK OF A SALIVARY GLAND MALIGNANCY.

  15. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESMUCOEPIDERMOID CARCINOMA • MUCOUS AND EPIDERMOID CELL ORIGIN • 6%OF ALL PAROTID TUMORS - MOST COMMON MALIGNANCY • 65%FOUND IN THE PAROTID GLAND • 18%OF ALL MALIGNANT TUMORS OF THE SALIVARY GLANDS

  16. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESMUCOEPIDERMOID CARCINOMA • LOW, INTERMEDIATE AND HIGH GRADES • 4-6TH DECADE • 8%CN VII INVOLVEMENT AT THE TIME OF PRESENTATION • 10%LYMPH NODE METASTASIS

  17. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESMUCOEPIDERMOID CARCINOMA • TREATMENT: TOTAL GLANDULAR RESECTION +/- NECK NODE DISSECTION • CN VII: SPARE NERVE UNLESS INVOLVED WITH TUMOR. • POSTOPERATIVE RADIOTHERAPY DEPENDING ON MARGINS, EXTRACAPSULAR EXTENSION FROM LYMPH NODES, PERINEURAL INVOLVEMENT, OR INVOLVEMENT OF SURROUNDING STRUCTURES

  18. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESMUCOEPIDERMOID CARCINOMA • RECURRENCE RATE 15-25%, USUALLY DUE TO INADEQUATE RESECTION. • WHEN MUCUOEPIDERMOID CARCINOMA IS LOCATED IN THE SUBMANDIBULAR GLAND, THE TUMOR IS MORE AGGRESSIVE. • RARELY INVOLVES THE SUBLINGUAL GLAND

  19. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESADENOID CYSTIC CARCINOMA (CYLINDROMA) • MOST COMMON MALIGNANT TUMOR OF THE SUBMANDIBULAR GLANDS AND THE SECOND MOST COMMON PAROTID MALIGNANCY • 25-30%CN VII PARALYSIS/PARESIS ON PRESENTATION • PERINEURAL INVASION IS COMMON • GRAY PINK WITH CRIBRIFORM HISTOLOGY

  20. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESADENOID CYSTIC CARCINOMA (CYLINDROMA) • UNPREDICTABLE TUMOR • SLOW GROWING, HOWEVER, RELENTLESS DISEASE • LUNG METASTASIS COMMON • LYMPH NODE INVOLVEMENT NOT COMMON

  21. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESADENOID CYSTIC CARCINOMA (CYLINDROMA) • TREATMENT: SURGICAL RESECTION OF THE GLAND WITH POSSIBLE NERVE RESECTION IF INVOLVED • POSTOPERATIVE RADIOTHERAPY

  22. MALIGNANT PLEOMORPHIC ADENOMA (MALIGNANT MIXED TUMOR OR CARCINOMA EX PLEOMORPHIC ADENOMA) • ETIOLOGY: MALIGNANT TRANSFORMATION OF A PLEOMORPHIC ADENOMA • 5-6TH DECADE • AVERAGE DURATION OF THE LESION IS PRESENT 10 YEARS BEFORE BEING DIAGNOSED • TREATMENT: GLANDULAR RESECTION WITH NERVE RESECTION IF INVOLVED WITH TUMOR

  23. ACINOUS (ACINIC) CELL CARCINOMA • LOW, INTERMEDIATE AND HIGH GRADE • INTRAVASCULAR EXTENSION • 3RD-6TH DECADE • METASTASIS TO THE LUNG AND BONE (VERTEBRAE) • TREATMENT: GLANDULAR RESECTION • RADIOTHERAPY IS NOT EFFECTIVE

  24. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESSQUAMOUS CELL CARCINOMA • IS IT A METASTATIC LESION? • 1/3HAVE FACIAL NERVE INVOLVEMENT AT THE TIME OF PRESENTATION • MALE > FEMALE • 6TH DECADE • TOTAL GLANDULAR RESECTION • 10YEAR SURVIVAL: 45%

  25. ADENOCARCINOMA • USUALLY FIXED TO THE SURROUNDING STRUCTURES • MALE > FEMALE • 3RD - 6TH DECADE • 22%FACIAL NERVE INVOLVEMENT AT THE TIME OF PRESENTATION • 25%METASTASIS AT THE TIME OF PRESENTATION • GLANDULAR RESECTION WITH NERVE RESECTION IF INVOLVED WITH TUMOR • NECK DISSECTION • POSTOPERATIVE RADIOTHERAPY

  26. TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSESUNDIFFERENTIATED CARCINOMA • 7TH-8TH DECADE • 33%FACIAL NERVE INVOLVEMENT AT THE TIME OF PRESENTATION • HIGHLY MALIGNANT • TREATMENT: GLANDULAR RESECTION, NECK DISSECTION, POSTOPERATIVE RADIOTHERAPY • NERVE RESECTION IF INVOLVED

  27. TUMORS OF THE SALIVARY GLANDS COMPLICATIONS OF SURGICAL INTERVENTION • ORAL FISTULAS • FACIAL NERVE INJURY • LOSS OF EAR SENSATION • FREY’S SYNDROME (GUSTATORY SWEATING) • SKIN NECROSIS

More Related